COVID-19
Conditions
Keywords
COVID-19, SARS-CoV-2, Master Protocol, Omicron, mRNA
Brief summary
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults previously vaccinated with SARS-CoV-2 mRNA vaccines.
Detailed description
There will be dose-escalation in part A of the study with sentinel dosing strategy implemented in each of 3 dosing levels (Group 1; 2; 3). At start, enrollment in Group 1 and 2 will occur simultaneously with the enrolment of 1st participant in Group 1. Each group will consist of 8 sentinel participants, with 6 receiving the mRNA-CR-04 vaccine and 2 receiving a placebo. The safety data from the sentinel participants in both groups, up to Day 8 post-vaccination, will be reviewed by the Internal Safety Review Committee (iSRC). If no safety signal is observed, vaccination of the non-sentinel participants in that group will continue. If there are no safety signals observed from the sentinel participants in Group 1 and Group 2, the enrollment and vaccination of the sentinel participants in Group 3 will begin. Part B of the study will commence only after all Part A participants have completed their Day 15 study visits and the Day 15 interim analysis is completed. In Part B, 2 doses of the mRNA-CR-04 vaccine will be evaluated.
Interventions
BIOLOGICALmRNA-CR-04 vaccine 10μg
mRNA CR-04 vaccine, 10 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
BIOLOGICALmRNA-CR-04 vaccine 30μg
mRNA CR-04 vaccine, 30 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
BIOLOGICALmRNA-CR-04 vaccine 100μg
mRNA CR-04 vaccine, 100 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
DRUGPlacebo
Placebo is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
BIOLOGICALmRNA-CR-04 vaccine 3μg
mRNA CR-04 vaccine, 3 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Data will be collected in an observer-blind manner.
Intervention model description
Dose escalation with sentinel dosing.
Eligibility
Sex/Gender
ALL
Age
18 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
1. Written or witnessed informed consent obtained from the participant prior to performance of any study-specific procedure. 2. Participants, who in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiary and study procedures). 3. Has received 2 doses of primary series and booster dose(s) of an authorized or licensed mRNA COVID-19 vaccine (only Moderna or Pfizer vaccines) with the last booster dose administered between at least 6 and 18 months or more prior to screening and has provided documentation of receiving the vaccination series (e.g., vaccination card). 4. Negative for SARS-CoV-2 infection by RT-PCR test at screening within 7 days prior to study vaccination. 5. Is a male or nonpregnant female of 18 to 49 years, inclusive, at screening. 6. If the participant is a woman of childbearing potential (WOCBP), the participant agrees to practice true abstinence or use at least 1 highly effective form of contraception for at least 30 days prior to study vaccination up to 1 month after study vaccination. 7. Agrees to refrain from blood or plasma donation from screening and up to 6 months after vaccination. 8. Is healthy or medically stable as determined by investigator judgment based on medical history, clinical laboratory tests, vital sign measurements, and physical examination findings.
Exclusion criteria
1. Has a new onset, clinically significant, abnormal biochemistry or hematology finding \[defined as greater than or equal to (\>=) Grade 1\] at screening (participants with Grade 1 laboratory abnormalities that have been stable for at least 6 months before enrollment may be included in the study). 2. Has any medical disease or condition that, in the opinion of the investigator, precludes study participation. This includes any acute, subacute, intermittent, or chronic medical disease or condition that would place the participant at an unacceptable risk of injury, render the participant unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the participant's successful completion of the trial. 3. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). 4. History of myocarditis, pericarditis, second- and third-degree heart block or idiopathic cardiomyopathy, or presence of any medical condition that increases risk of myocarditis or pericarditis, including cocaine abuse, cardiomyopathy, endomyocardial fibrosis, hypereosinophilic syndrome, hypersensitivity myocarditis eosinophilic granulomatosis with polyangiitis, persistent myocardial viral infection (e.g., due to enterovirus or adenovirus). 5. Has an acute febrile illness with a temperature \>=38.0 degree Celsius (°C) or \>=100.4 degree Fahrenheit (°F) observed by the participant or at the study site within 72 hours prior to study vaccination. Participants with suspected COVID-19 symptoms should be excluded and referred for medical care. 6. Has a history of hypersensitivity or severe allergic reaction, including anaphylaxis, generalized urticaria, angioedema, and other significant reactions to any previous vaccine, or any component of the study vaccine. 7. Has a body mass index greater than (\>) 40 Kilograms meter per square (kg/m\^2). 8. Has had known close contact with anyone who had a confirmed SARS-CoV-2 infection within 14 days before study vaccination. 9. Has a history of documented SARS-CoV-2 infection or COVID-19 within 6 months before the date of screening visit. 10. Has any self-reported or medically documented clinically significant medical or psychiatric condition. Significant medical conditions include, but are not limited to, the following: 1. Moderate or severe respiratory disease (e.g., chronic obstructive pulmonary disease, asthma). 2. Uncontrolled hypertension, defined as an average systolic blood pressure \>= 140 millimeters of mercury (mmHg) or an average diastolic blood pressure \>= 90 mmHg, based on an average of up to 3 blood pressure measurements. 3. Clinically significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease). 4. Neurological or neurodevelopmental conditions (e.g., Down syndrome, dementia, chronic migraine not controlled by medication, epilepsy, stroke or seizures in the last 3 years, encephalopathy, focal neurologic deficits, Guillain- Barré syndrome, encephalomyelitis, or transverse myelitis). 5. Ongoing malignancy or recent diagnosis of malignancy in the last 5 years (excluding basal cell and squamous cell carcinoma of the skin). 6. Tuberculosis or non-tuberculosis mycobacterial infection. 7. Autoimmune disease, including hypothyroidism without a defined nonautoimmune cause. 8. Immunodeficiency of any cause, including from solid organ transplant, blood, or bone marrow transplant, or use of other immune-weakening medicine. 9. Type 1 or 2 diabetes mellitus regardless of disease control. 11. Has any of the following self-reported or medically documented risk factors for severe COVID-19: 1. Chronic kidney disease 2. Cerebrovascular disease 3. Cystic fibrosis 4. Chronic liver disease 5. Pulmonary fibrosis 12. Has participated or plans to participate in another investigational study involving any investigational drug or device within 60 days or 5 half-lives, whichever is longer, before study vaccination and throughout the study. 13. Has received a licensed or authorized non-mRNA COVID-19 vaccine (primary series or booster dose). 14. Has received or plans to receive any licensed vaccine within 4 weeks before or after study vaccination. Inactivated vaccines for influenza are permitted during the study if they are administered at least 14 days before or after study vaccination. 15. Is planning to receive an authorized or licensed COVID-19 booster vaccination for the duration of the study (for participants who are not covered by local recommendations to receive booster per current standard of care) OR is planning to receive an authorized or licensed COVID-19 booster vaccination on or before Day 31 of the study (for participants covered by local recommendations to receive booster). 16. Has received or plans to receive immunoglobulins or any blood or blood products within 90 days before study vaccination and throughout the study. 17. Reports chronic use (more than 14 continuous days) of any medication that may be associated with changes in immune function including, but not limited to, systemic corticosteroids exceeding 20 mg/day of prednisone equivalent, allergy injections, immunoglobulins, interferons, immunomodulators, cytotoxic drugs, or other similar or toxic drugs within 6 months of study vaccination. Note: The use of low-dose topical, ophthalmic, inhaled, intra-articular and intranasal steroid preparations is permitted. 18. Pregnant or lactating female. 19. Female participant planning to become pregnant or planning to discontinue contraceptive precautions within 1 month following study vaccination. 20. Participant is an employee or family member of the investigator or study site personnel.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Any Adverse Events of Special Interest (AESIs) | Day 1 to Day 31 | AESIs include potential immune-mediated diseases (pIMDs) which are autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology, myocarditis, and pericarditis, virologically confirmed COVID-19 cases, anaphylaxis, or severe hypersensitivity within 24 hours after study investigational product administration. Any = occurrence of the event regardless of intensity grade. |
| Number of Participants With Any Solicited Administration Site Events | Day 1 to Day 7 | The solicited administration site events are pain, redness, swelling and lymphadenopathy (axillary swelling/ tenderness on the same side of the body as the site of injection). Any = occurrence of the event regardless of intensity grade. |
| Number of Participants With Any Solicited Systemic Events | Day 1 to Day 7 | The solicited systemic events are fever, headache, myalgia (muscle pain), arthralgia (joint pain), fatigue (tiredness), chills, abdominal pain, vomiting and diarrhea. Fever is defined as body temperature ≥38ºC; preferred location for measuring the temperature is oral. Any = occurrence of the event regardless of intensity grade. |
| Number of Participants With Any Unsolicited Adverse Events (AEs) | Day 1 to Day 30 | An unsolicited AE is an AE that is either not included in the list of solicited events or can be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs include both serious and nonserious AEs. Any = occurrence of the event regardless of intensity grade. |
| Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Day 1 to Day 15 | The hematological and biochemical parameters included alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), total bilirubin, creatinine, direct bilirubin, basophils, eosinophils increase, erytrocytes, hemoglobin decrease, lymphocytes decrease, mean corpuscular hemoglobin, mean corpuscular volume, monocytes, neutrophils decrease, platelets decrease, white blood cells (WBC) increase. Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. |
| Number of Participants With Any Medically Attended Adverse Events (MAAEs) | Day 1 to Day 31 | A MAAE is an AE for which the participant received medical attention including any symptom or illness requiring hospitalization, or an emergency room visit, or visit to/by a healthcare professional. Any = occurrence of the event regardless of intensity grade. |
| Number of Participants With Any Serious Adverse Events (SAEs) | Day 1 to Day 31 | An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcome or any other situation as determined by the investigator. Any = occurrence of the event regardless of intensity grade. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Any SAEs | Throughout the study period (Day 1 to Month 6) | An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcome or any other situation as determined by the investigator. Any = occurrence of the event regardless of intensity grade. |
| Number of Participants With Any AESIs | Throughout the study period (Day 1 to Month 6) | AESIs include potential immune-mediated diseases (pIMDs) which are autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology, myocarditis, and pericarditis, virologically confirmed COVID-19 cases, anaphylaxis, or severe hypersensitivity within 24 hours after study investigational product administration. Any = occurrence of the event regardless of intensity grade. |
| Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | At Days 1, 15 and 31, and at Month 6 | The analyzed neutralizing titers were SARS-CoV-2 Neutralizing Titer BA.5 and SARS-CoV-2 Neutralizing Titer D614G. D= Day; M= Month. |
| Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | At Days 15 and 31, and at Month 6 (compared with baseline [Day 1]) | The analyzed neutralizing titers were SARS-CoV-2 Neutralizing Titer BA.5 and SARS-CoV-2 Neutralizing Titer D614G. D= Day; M= Month. |
| Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | At Days 15 and 31, and at Month 6 (compared with baseline [Day 1]) | VRR is expressed as the number of participants with a vaccine response, defined as at least a 4-fold greater neutralizing titer as compared to the titer at Day 1. D= Day; M= Month. |
| Number of Participants With Any MAAEs | Throughout the study period (Day 1 to Month 6) | A MAAE is an AE for which the participant received medical attention including any symptom or illness requiring hospitalization, or an emergency room visit, or visit to/by a healthcare professional. Any = occurrence of the event regardless of intensity grade. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Part A, Group 1: mRNA CR-04 10 µg Participants received mRNA 10 micrograms (µg) administered on Day 1. | 18 |
| Part A, Group 1: Placebo Participants received placebo dose administered on Day 1. | 6 |
| Part A, Group 2: mRNA CR-04 30 µg Participants received mRNA 30 µg administered on Day 1. | 18 |
| Part A, Group 2: Placebo Participants received placebo dose administered on Day 1. | 6 |
| Part A, Group 3: mRNA CR-04 100 µg Participants received mRNA 100 µg administered on Day 1. | 18 |
| Part A, Group 3: Placebo Participants received placebo dose administered on Day 1. | 6 |
| Part B: mRNA CR-04 3 µg Participants received mRNA 3 µg administered on Day 1. | 18 |
| Part B: mRNA CR-04 10 µg Participants received mRNA 10 µg administered on Day 1. | 18 |
| Part B: Placebo Participants received placebo dose administered on Day 1. | 6 |
| Total | 114 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 |
|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 |
Baseline characteristics
| Characteristic | Part A, Group 1: mRNA CR-04 10 µg | Part A, Group 1: Placebo | Part A, Group 2: mRNA CR-04 30 µg | Part A, Group 2: Placebo | Part A, Group 3: mRNA CR-04 100 µg | Part A, Group 3: Placebo | Part B: mRNA CR-04 3 µg | Part B: mRNA CR-04 10 µg | Part B: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 38.9 Years STANDARD_DEVIATION 9.8 | 40.2 Years STANDARD_DEVIATION 8.3 | 39.2 Years STANDARD_DEVIATION 7.9 | 35.8 Years STANDARD_DEVIATION 7 | 34.7 Years STANDARD_DEVIATION 8 | 37.2 Years STANDARD_DEVIATION 8.8 | 35.7 Years STANDARD_DEVIATION 10.5 | 37.7 Years STANDARD_DEVIATION 7.9 | 41.5 Years STANDARD_DEVIATION 7.7 | 37.7 Years STANDARD_DEVIATION 8.7 |
| Race/Ethnicity, Customized All Other Races | 17 Participants | 5 Participants | 18 Participants | 5 Participants | 17 Participants | 6 Participants | 17 Participants | 18 Participants | 5 Participants | 108 Participants |
| Race/Ethnicity, Customized Not reported | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 6 Participants |
| Sex: Female, Male Female | 10 Participants | 3 Participants | 10 Participants | 4 Participants | 12 Participants | 4 Participants | 8 Participants | 10 Participants | 3 Participants | 64 Participants |
| Sex: Female, Male Male | 8 Participants | 3 Participants | 8 Participants | 2 Participants | 6 Participants | 2 Participants | 10 Participants | 8 Participants | 3 Participants | 50 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 18 | 0 / 6 | 0 / 18 | 0 / 6 | 0 / 18 | 0 / 6 | 0 / 18 | 0 / 18 | 0 / 6 |
| other Total, other adverse events | 12 / 18 | 2 / 6 | 15 / 18 | 3 / 6 | 16 / 18 | 4 / 6 | 16 / 18 | 10 / 18 | 4 / 6 |
| serious Total, serious adverse events | 1 / 18 | 0 / 6 | 1 / 18 | 0 / 6 | 0 / 18 | 0 / 6 | 0 / 18 | 0 / 18 | 0 / 6 |
Outcome results
Primary
Number of Participants With Any Adverse Events of Special Interest (AESIs)
AESIs include potential immune-mediated diseases (pIMDs) which are autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology, myocarditis, and pericarditis, virologically confirmed COVID-19 cases, anaphylaxis, or severe hypersensitivity within 24 hours after study investigational product administration. Any = occurrence of the event regardless of intensity grade.
Time frame: Day 1 to Day 31
Population: Analysis was performed on Exposed set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Adverse Events of Special Interest (AESIs) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Adverse Events of Special Interest (AESIs) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Adverse Events of Special Interest (AESIs) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Adverse Events of Special Interest (AESIs) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Adverse Events of Special Interest (AESIs) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Adverse Events of Special Interest (AESIs) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Adverse Events of Special Interest (AESIs) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Adverse Events of Special Interest (AESIs) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Adverse Events of Special Interest (AESIs) | 0 Participants |
Primary
Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities
The hematological and biochemical parameters included alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), total bilirubin, creatinine, direct bilirubin, basophils, eosinophils increase, erytrocytes, hemoglobin decrease, lymphocytes decrease, mean corpuscular hemoglobin, mean corpuscular volume, monocytes, neutrophils decrease, platelets decrease, white blood cells (WBC) increase. Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Time frame: Day 1 to Day 15
Population: Analysis was performed on Exposed set. Only participants with data available at specified timepoints were included in analysis.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Above (Day 15) | 2 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Within (Day 15) | 3 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Within (Day 15) | 12 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Within (Day 15) | 10 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Below (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Below (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Below (Day 15) | 2 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Within (Day 15) | 2 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Below (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Below (Day 15) | 2 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Above (Day 15) | 3 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Within (Day 15) | 15 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Below (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Below (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Within (Day 15) | 14 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Within (Day 15) | 15 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Below (Day 15) | 2 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Within (Day 15) | 14 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Below (Day 15) | 2 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Within (Day 15) | 4 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Within (Day 15) | 5 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Within (Day 15) | 5 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Within (Day 15) | 5 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Within (Day 15) | 5 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Below (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Above (Day 15) | 2 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Within (Day 15) | 13 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Below (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Within (Day 15) | 14 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Below (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Below (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Below (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Within (Day 15) | 15 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Within (Day 15) | 15 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Within (Day 15) | 15 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Within (Day 15) | 13 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Above (Day 15) | 2 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Within (Day 15) | 5 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Within (Day 15) | 3 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Below (Day 15) | 2 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Within (Day 15) | 5 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Within (Day 15) | 5 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Within (Day 15) | 5 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Below (Day 15) | 1 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Within (Day 15) | 15 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Above (Day 15) | 2 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Below (Day 15) | 1 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Above (Day 15) | 2 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Within (Day 15) | 2 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Within (Day 15) | 14 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Within (Day 15) | 5 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Below (Day 15) | 1 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Within (Day 15) | 4 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Within (Day 15) | 5 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Within (Day 15) | 5 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Within (Day 15) | 15 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Below (Day 15) | 1 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Within (Day 15) | 14 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Below (Day 15) | 1 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Within (Day 15) | 15 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Within (Day 15) | 1 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Within (Day 15) | 1 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Within (Day 15) | 14 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Below (Day 15) | 1 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Within (Day 15) | 14 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Below (Day 15) | 1 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Below (Day 15) | 1 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Below (Day 15) | 2 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Within (Day 15) | 17 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Below (Day 15) | 1 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Within (Day 15) | 1 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Within (Day 15) | 16 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Within (Day 15) | 18 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Within (Day 15) | 1 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Within (Day 15) | 15 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Within (Day 15) | 5 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Eosinophils Increase | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Below (Day 15) | 2 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Within (Baseline) - Within (Day 15) | 4 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Above (Baseline) - Above (Day 15) | 1 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Neutrophils Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Erythrocytes | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Hemoglobin Decrease | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Within (Baseline) - Within (Day 15) | 4 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Monocytes | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | AST | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Direct Bilirubin | Above (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Within (Baseline) - Above (Day 15) | 1 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Total Bilirubin | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Volume | Within (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Within (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Within (Baseline) - Within (Day 15) | 6 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | WBC Increase | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Lymphocytes Decrease | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Above (Baseline) - Below (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Creatinine | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Basophils | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALP | Below (Baseline) - Above (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Platelets Decrease | Below (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | Mean Corpuscular Hemoglobin | Above (Baseline) - Within (Day 15) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Hematological and Biochemical Laboratory Abnormalities | ALT | Below (Baseline) - Below (Day 15) | 1 Participants |
Primary
Number of Participants With Any Medically Attended Adverse Events (MAAEs)
A MAAE is an AE for which the participant received medical attention including any symptom or illness requiring hospitalization, or an emergency room visit, or visit to/by a healthcare professional. Any = occurrence of the event regardless of intensity grade.
Time frame: Day 1 to Day 31
Population: Analysis was performed on Exposed set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Medically Attended Adverse Events (MAAEs) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Medically Attended Adverse Events (MAAEs) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Medically Attended Adverse Events (MAAEs) | 1 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Medically Attended Adverse Events (MAAEs) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Medically Attended Adverse Events (MAAEs) | 2 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Medically Attended Adverse Events (MAAEs) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Medically Attended Adverse Events (MAAEs) | 2 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Medically Attended Adverse Events (MAAEs) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Medically Attended Adverse Events (MAAEs) | 0 Participants |
Primary
Number of Participants With Any Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcome or any other situation as determined by the investigator. Any = occurrence of the event regardless of intensity grade.
Time frame: Day 1 to Day 31
Population: Analysis was performed on Exposed set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Serious Adverse Events (SAEs) | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Serious Adverse Events (SAEs) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Serious Adverse Events (SAEs) | 1 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Serious Adverse Events (SAEs) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Serious Adverse Events (SAEs) | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Serious Adverse Events (SAEs) | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Serious Adverse Events (SAEs) | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Serious Adverse Events (SAEs) | 0 Participants |
| Part B: Placebo | Number of Participants With Any Serious Adverse Events (SAEs) | 0 Participants |
Primary
Number of Participants With Any Solicited Administration Site Events
The solicited administration site events are pain, redness, swelling and lymphadenopathy (axillary swelling/ tenderness on the same side of the body as the site of injection). Any = occurrence of the event regardless of intensity grade.
Time frame: Day 1 to Day 7
Population: Analysis was performed on Solicited Safety Set (SSS) which includes all participants who received at least one dose of investigational products and had solicited events data at the specified timepoints.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Solicited Administration Site Events | Pain at administration site | 8 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Solicited Administration Site Events | Lymphadenopathy | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Solicited Administration Site Events | Swelling at administration site | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Solicited Administration Site Events | Redness at administration site | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Solicited Administration Site Events | Redness at administration site | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Solicited Administration Site Events | Pain at administration site | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Solicited Administration Site Events | Lymphadenopathy | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Solicited Administration Site Events | Swelling at administration site | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Solicited Administration Site Events | Lymphadenopathy | 2 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Solicited Administration Site Events | Pain at administration site | 10 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Solicited Administration Site Events | Redness at administration site | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Solicited Administration Site Events | Swelling at administration site | 1 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Solicited Administration Site Events | Swelling at administration site | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Solicited Administration Site Events | Lymphadenopathy | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Solicited Administration Site Events | Redness at administration site | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Solicited Administration Site Events | Pain at administration site | 1 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Solicited Administration Site Events | Pain at administration site | 15 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Solicited Administration Site Events | Lymphadenopathy | 2 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Solicited Administration Site Events | Redness at administration site | 4 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Solicited Administration Site Events | Swelling at administration site | 3 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Solicited Administration Site Events | Lymphadenopathy | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Solicited Administration Site Events | Redness at administration site | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Solicited Administration Site Events | Swelling at administration site | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Solicited Administration Site Events | Pain at administration site | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Solicited Administration Site Events | Swelling at administration site | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Solicited Administration Site Events | Redness at administration site | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Solicited Administration Site Events | Lymphadenopathy | 2 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Solicited Administration Site Events | Pain at administration site | 9 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Solicited Administration Site Events | Redness at administration site | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Solicited Administration Site Events | Swelling at administration site | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Solicited Administration Site Events | Pain at administration site | 6 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Solicited Administration Site Events | Lymphadenopathy | 3 Participants |
| Part B: Placebo | Number of Participants With Any Solicited Administration Site Events | Redness at administration site | 0 Participants |
| Part B: Placebo | Number of Participants With Any Solicited Administration Site Events | Pain at administration site | 1 Participants |
| Part B: Placebo | Number of Participants With Any Solicited Administration Site Events | Lymphadenopathy | 0 Participants |
| Part B: Placebo | Number of Participants With Any Solicited Administration Site Events | Swelling at administration site | 0 Participants |
Primary
Number of Participants With Any Solicited Systemic Events
The solicited systemic events are fever, headache, myalgia (muscle pain), arthralgia (joint pain), fatigue (tiredness), chills, abdominal pain, vomiting and diarrhea. Fever is defined as body temperature ≥38ºC; preferred location for measuring the temperature is oral. Any = occurrence of the event regardless of intensity grade.
Time frame: Day 1 to Day 7
Population: Analysis was performed on SSS which includes all participants who received at least one dose of investigational products and had solicited events data at the specified timepoints.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Fever | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Abdominal Pain | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Chills | 2 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Headache | 5 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Fatigue | 8 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Vomiting | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Diarrhea | 0 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Myalgia | 4 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Arthralgia | 1 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Solicited Systemic Events | Myalgia | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Solicited Systemic Events | Vomiting | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Solicited Systemic Events | Chills | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Solicited Systemic Events | Arthralgia | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Solicited Systemic Events | Diarrhea | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Solicited Systemic Events | Fever | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Solicited Systemic Events | Fatigue | 1 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Solicited Systemic Events | Headache | 1 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Solicited Systemic Events | Abdominal Pain | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Solicited Systemic Events | Abdominal Pain | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Solicited Systemic Events | Chills | 3 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Solicited Systemic Events | Diarrhea | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Solicited Systemic Events | Fever | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Solicited Systemic Events | Myalgia | 4 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Solicited Systemic Events | Vomiting | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Solicited Systemic Events | Arthralgia | 3 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Solicited Systemic Events | Headache | 4 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Solicited Systemic Events | Fatigue | 7 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Solicited Systemic Events | Arthralgia | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Solicited Systemic Events | Myalgia | 2 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Solicited Systemic Events | Abdominal Pain | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Solicited Systemic Events | Headache | 1 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Solicited Systemic Events | Diarrhea | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Solicited Systemic Events | Fever | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Solicited Systemic Events | Chills | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Solicited Systemic Events | Fatigue | 1 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Solicited Systemic Events | Vomiting | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Solicited Systemic Events | Vomiting | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Solicited Systemic Events | Headache | 8 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Solicited Systemic Events | Arthralgia | 2 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Solicited Systemic Events | Diarrhea | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Solicited Systemic Events | Myalgia | 11 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Solicited Systemic Events | Fever | 3 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Solicited Systemic Events | Abdominal Pain | 1 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Solicited Systemic Events | Chills | 3 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Solicited Systemic Events | Fatigue | 8 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Solicited Systemic Events | Chills | 1 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Solicited Systemic Events | Fever | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Solicited Systemic Events | Myalgia | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Solicited Systemic Events | Arthralgia | 1 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Solicited Systemic Events | Headache | 2 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Solicited Systemic Events | Fatigue | 2 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Solicited Systemic Events | Abdominal Pain | 1 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Solicited Systemic Events | Vomiting | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Solicited Systemic Events | Diarrhea | 1 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Solicited Systemic Events | Arthralgia | 1 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Solicited Systemic Events | Fever | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Solicited Systemic Events | Vomiting | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Solicited Systemic Events | Chills | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Solicited Systemic Events | Myalgia | 6 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Solicited Systemic Events | Diarrhea | 1 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Solicited Systemic Events | Abdominal Pain | 1 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Solicited Systemic Events | Fatigue | 7 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Solicited Systemic Events | Headache | 6 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Fever | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Fatigue | 5 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Arthralgia | 2 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Abdominal Pain | 1 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Myalgia | 8 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Diarrhea | 1 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Vomiting | 2 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Headache | 4 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Solicited Systemic Events | Chills | 2 Participants |
| Part B: Placebo | Number of Participants With Any Solicited Systemic Events | Fever | 0 Participants |
| Part B: Placebo | Number of Participants With Any Solicited Systemic Events | Headache | 2 Participants |
| Part B: Placebo | Number of Participants With Any Solicited Systemic Events | Arthralgia | 0 Participants |
| Part B: Placebo | Number of Participants With Any Solicited Systemic Events | Chills | 1 Participants |
| Part B: Placebo | Number of Participants With Any Solicited Systemic Events | Abdominal Pain | 0 Participants |
| Part B: Placebo | Number of Participants With Any Solicited Systemic Events | Diarrhea | 1 Participants |
| Part B: Placebo | Number of Participants With Any Solicited Systemic Events | Myalgia | 0 Participants |
| Part B: Placebo | Number of Participants With Any Solicited Systemic Events | Fatigue | 1 Participants |
| Part B: Placebo | Number of Participants With Any Solicited Systemic Events | Vomiting | 0 Participants |
Primary
Number of Participants With Any Unsolicited Adverse Events (AEs)
An unsolicited AE is an AE that is either not included in the list of solicited events or can be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs include both serious and nonserious AEs. Any = occurrence of the event regardless of intensity grade.
Time frame: Day 1 to Day 30
Population: Analysis was performed on Exposed set, which included all participants who received the dose of the investigational products.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any Unsolicited Adverse Events (AEs) | 6 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any Unsolicited Adverse Events (AEs) | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any Unsolicited Adverse Events (AEs) | 5 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any Unsolicited Adverse Events (AEs) | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any Unsolicited Adverse Events (AEs) | 4 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any Unsolicited Adverse Events (AEs) | 3 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any Unsolicited Adverse Events (AEs) | 8 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any Unsolicited Adverse Events (AEs) | 2 Participants |
| Part B: Placebo | Number of Participants With Any Unsolicited Adverse Events (AEs) | 1 Participants |
Secondary
Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains
The analyzed neutralizing titers were SARS-CoV-2 Neutralizing Titer BA.5 and SARS-CoV-2 Neutralizing Titer D614G. D= Day; M= Month.
Time frame: At Days 15 and 31, and at Month 6 (compared with baseline [Day 1])
Population: Analysis was performed on PPS. Only participants with data available at the specified timepoints were included in the analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Part A, Group 1: mRNA CR-04 10 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, M6 | 1.99 Ratio |
| Part A, Group 1: mRNA CR-04 10 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D31 | 8.57 Ratio |
| Part A, Group 1: mRNA CR-04 10 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D15 | 4.68 Ratio |
| Part A, Group 1: mRNA CR-04 10 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D15 | 9.25 Ratio |
| Part A, Group 1: mRNA CR-04 10 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, M6 | 2.76 Ratio |
| Part A, Group 1: mRNA CR-04 10 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D31 | 3.50 Ratio |
| Part A, Group 1: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D15 | 10.22 Ratio |
| Part A, Group 1: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D15 | 5.80 Ratio |
| Part A, Group 1: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, M6 | 2.08 Ratio |
| Part A, Group 1: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D31 | 7.37 Ratio |
| Part A, Group 1: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D31 | 4.32 Ratio |
| Part A, Group 1: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, M6 | 2.64 Ratio |
| Part A, Group 2: mRNA CR-04 30 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D31 | 6.91 Ratio |
| Part A, Group 2: mRNA CR-04 30 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, M6 | 3.74 Ratio |
| Part A, Group 2: mRNA CR-04 30 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, M6 | 2.43 Ratio |
| Part A, Group 2: mRNA CR-04 30 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D15 | 8.44 Ratio |
| Part A, Group 2: mRNA CR-04 30 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D15 | 10.38 Ratio |
| Part A, Group 2: mRNA CR-04 30 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D31 | 13.46 Ratio |
| Part A, Group 2: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D31 | 0.89 Ratio |
| Part A, Group 2: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D15 | 0.98 Ratio |
| Part A, Group 2: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D31 | 0.86 Ratio |
| Part A, Group 2: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, M6 | 0.87 Ratio |
| Part A, Group 2: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D15 | 0.96 Ratio |
| Part A, Group 2: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, M6 | 1.28 Ratio |
| Part A, Group 3: mRNA CR-04 100 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D15 | 2.53 Ratio |
| Part A, Group 3: mRNA CR-04 100 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D31 | 3.43 Ratio |
| Part A, Group 3: mRNA CR-04 100 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D31 | 2.43 Ratio |
| Part A, Group 3: mRNA CR-04 100 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, M6 | 2.01 Ratio |
| Part A, Group 3: mRNA CR-04 100 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, M6 | 2.26 Ratio |
| Part A, Group 3: mRNA CR-04 100 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D15 | 3.91 Ratio |
| Part A, Group 3: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, M6 | 2.45 Ratio |
| Part A, Group 3: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D15 | 3.45 Ratio |
| Part A, Group 3: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D31 | 4.53 Ratio |
| Part A, Group 3: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D31 | 3.98 Ratio |
| Part A, Group 3: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D15 | 5.80 Ratio |
| Part A, Group 3: Placebo | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, M6 | 1.65 Ratio |
| Part B: mRNA CR-04 3 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, M6 | 0.79 Ratio |
| Part B: mRNA CR-04 3 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D31 | 0.96 Ratio |
| Part B: mRNA CR-04 3 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, M6 | 1.27 Ratio |
| Part B: mRNA CR-04 3 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D15 | 1.15 Ratio |
| Part B: mRNA CR-04 3 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D31 | 1.48 Ratio |
| Part B: mRNA CR-04 3 µg | Geometric Mean Ratio (GMR) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D15 | 0.95 Ratio |
Secondary
Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains
The analyzed neutralizing titers were SARS-CoV-2 Neutralizing Titer BA.5 and SARS-CoV-2 Neutralizing Titer D614G. D= Day; M= Month.
Time frame: At Days 1, 15 and 31, and at Month 6
Population: Analysis was performed on Per Protocol Set (PPS) which included participants who received investigational products, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination, who have neutralizing titer values against pseudovirus bearing S protein data, and without major protocol deviations. Only participants with data available at the specified timepoints were included in the analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Part A, Group 1: mRNA CR-04 10 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D31 | 4197.66 Titers |
| Part A, Group 1: mRNA CR-04 10 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D15 | 4271.90 Titers |
| Part A, Group 1: mRNA CR-04 10 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D1 | 550.72 Titers |
| Part A, Group 1: mRNA CR-04 10 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, M6 | 1414.22 Titers |
| Part A, Group 1: mRNA CR-04 10 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D1 | 2502.06 Titers |
| Part A, Group 1: mRNA CR-04 10 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D15 | 8073.12 Titers |
| Part A, Group 1: mRNA CR-04 10 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D31 | 6251.22 Titers |
| Part A, Group 1: mRNA CR-04 10 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, M6 | 3813.02 Titers |
| Part A, Group 1: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D15 | 4720.61 Titers |
| Part A, Group 1: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, M6 | 3970.88 Titers |
| Part A, Group 1: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D31 | 3607.13 Titers |
| Part A, Group 1: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, M6 | 1354.49 Titers |
| Part A, Group 1: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D1 | 1409.21 Titers |
| Part A, Group 1: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D15 | 9990.27 Titers |
| Part A, Group 1: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D31 | 7726.20 Titers |
| Part A, Group 1: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D1 | 526.95 Titers |
| Part A, Group 2: mRNA CR-04 30 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D31 | 6591.72 Titers |
| Part A, Group 2: mRNA CR-04 30 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, M6 | 4645.04 Titers |
| Part A, Group 2: mRNA CR-04 30 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, M6 | 1919.56 Titers |
| Part A, Group 2: mRNA CR-04 30 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D1 | 1820.75 Titers |
| Part A, Group 2: mRNA CR-04 30 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D15 | 14543.96 Titers |
| Part A, Group 2: mRNA CR-04 30 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D31 | 12351.27 Titers |
| Part A, Group 2: mRNA CR-04 30 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D15 | 4795.20 Titers |
| Part A, Group 2: mRNA CR-04 30 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D1 | 504.01 Titers |
| Part A, Group 2: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, M6 | 444.43 Titers |
| Part A, Group 2: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, M6 | 2441.97 Titers |
| Part A, Group 2: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D1 | 1421.87 Titers |
| Part A, Group 2: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D15 | 1654.35 Titers |
| Part A, Group 2: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D31 | 1585.37 Titers |
| Part A, Group 2: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D31 | 420.37 Titers |
| Part A, Group 2: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D1 | 320.87 Titers |
| Part A, Group 2: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D15 | 453.93 Titers |
| Part A, Group 3: mRNA CR-04 100 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D1 | 2139.66 Titers |
| Part A, Group 3: mRNA CR-04 100 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, M6 | 4059.06 Titers |
| Part A, Group 3: mRNA CR-04 100 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D15 | 4661.13 Titers |
| Part A, Group 3: mRNA CR-04 100 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D31 | 4633.14 Titers |
| Part A, Group 3: mRNA CR-04 100 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, M6 | 1547.09 Titers |
| Part A, Group 3: mRNA CR-04 100 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D1 | 689.36 Titers |
| Part A, Group 3: mRNA CR-04 100 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D15 | 2423.54 Titers |
| Part A, Group 3: mRNA CR-04 100 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D31 | 2157.80 Titers |
| Part A, Group 3: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D15 | 6363.85 Titers |
| Part A, Group 3: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, M6 | 3342.96 Titers |
| Part A, Group 3: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D31 | 7601.57 Titers |
| Part A, Group 3: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D1 | 1604.51 Titers |
| Part A, Group 3: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D1 | 574.02 Titers |
| Part A, Group 3: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D15 | 3596.47 Titers |
| Part A, Group 3: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D31 | 2847.07 Titers |
| Part A, Group 3: Placebo | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, M6 | 1677.07 Titers |
| Part B: mRNA CR-04 3 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D31 | 2819.98 Titers |
| Part B: mRNA CR-04 3 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D15 | 2129.10 Titers |
| Part B: mRNA CR-04 3 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, M6 | 2571.87 Titers |
| Part B: mRNA CR-04 3 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D1 | 493.05 Titers |
| Part B: mRNA CR-04 3 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D15 | 589.81 Titers |
| Part B: mRNA CR-04 3 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, D31 | 602.35 Titers |
| Part B: mRNA CR-04 3 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | BA.5, M6 | 540.16 Titers |
| Part B: mRNA CR-04 3 µg | Geometric Mean Titers (GMT) of Neutralizing Titers Against Pseudovirus Bearing S Protein From Vaccine Encoded SARS-CoV-2 and Wild Type (WT) Strains | D614G, D1 | 1702.33 Titers |
Secondary
Number of Participants With Any AESIs
AESIs include potential immune-mediated diseases (pIMDs) which are autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology, myocarditis, and pericarditis, virologically confirmed COVID-19 cases, anaphylaxis, or severe hypersensitivity within 24 hours after study investigational product administration. Any = occurrence of the event regardless of intensity grade.
Time frame: Throughout the study period (Day 1 to Month 6)
Population: Analysis was performed on Exposed set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any AESIs | 0 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any AESIs | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any AESIs | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any AESIs | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any AESIs | 1 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any AESIs | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any AESIs | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any AESIs | 0 Participants |
| Part B: Placebo | Number of Participants With Any AESIs | 0 Participants |
Secondary
Number of Participants With Any MAAEs
A MAAE is an AE for which the participant received medical attention including any symptom or illness requiring hospitalization, or an emergency room visit, or visit to/by a healthcare professional. Any = occurrence of the event regardless of intensity grade.
Time frame: Throughout the study period (Day 1 to Month 6)
Population: Analysis was performed on Exposed set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any MAAEs | 3 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any MAAEs | 1 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any MAAEs | 2 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any MAAEs | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any MAAEs | 3 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any MAAEs | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any MAAEs | 3 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any MAAEs | 0 Participants |
| Part B: Placebo | Number of Participants With Any MAAEs | 0 Participants |
Secondary
Number of Participants With Any SAEs
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcome or any other situation as determined by the investigator. Any = occurrence of the event regardless of intensity grade.
Time frame: Throughout the study period (Day 1 to Month 6)
Population: Analysis was performed on Exposed set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Any SAEs | 1 Participants |
| Part A, Group 1: Placebo | Number of Participants With Any SAEs | 0 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Any SAEs | 1 Participants |
| Part A, Group 2: Placebo | Number of Participants With Any SAEs | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Any SAEs | 0 Participants |
| Part A, Group 3: Placebo | Number of Participants With Any SAEs | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Any SAEs | 0 Participants |
| Part B: mRNA CR-04 10 µg | Number of Participants With Any SAEs | 0 Participants |
| Part B: Placebo | Number of Participants With Any SAEs | 0 Participants |
Secondary
Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains
VRR is expressed as the number of participants with a vaccine response, defined as at least a 4-fold greater neutralizing titer as compared to the titer at Day 1. D= Day; M= Month.
Time frame: At Days 15 and 31, and at Month 6 (compared with baseline [Day 1])
Population: Analysis was performed on PPS. Only participants with data available at specified timepoints were included in analysis.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D15 | 11 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D31 | 5 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D31 | 12 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, M6 | 3 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, M6 | 2 Participants |
| Part A, Group 1: mRNA CR-04 10 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D15 | 6 Participants |
| Part A, Group 1: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D15 | 8 Participants |
| Part A, Group 1: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, M6 | 3 Participants |
| Part A, Group 1: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, M6 | 3 Participants |
| Part A, Group 1: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D31 | 8 Participants |
| Part A, Group 1: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D31 | 12 Participants |
| Part A, Group 1: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D15 | 13 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, M6 | 4 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D15 | 14 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D31 | 15 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, M6 | 7 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D15 | 12 Participants |
| Part A, Group 2: mRNA CR-04 30 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D31 | 11 Participants |
| Part A, Group 2: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D15 | 2 Participants |
| Part A, Group 2: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D15 | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, M6 | 2 Participants |
| Part A, Group 2: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D31 | 0 Participants |
| Part A, Group 2: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, M6 | 1 Participants |
| Part A, Group 2: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D31 | 0 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, M6 | 2 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, M6 | 4 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D31 | 5 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D15 | 3 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D31 | 4 Participants |
| Part A, Group 3: mRNA CR-04 100 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D15 | 7 Participants |
| Part A, Group 3: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D15 | 13 Participants |
| Part A, Group 3: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D15 | 9 Participants |
| Part A, Group 3: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D31 | 11 Participants |
| Part A, Group 3: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D31 | 8 Participants |
| Part A, Group 3: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, M6 | 3 Participants |
| Part A, Group 3: Placebo | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, M6 | 3 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D15 | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, M6 | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D15 | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, M6 | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | BA.5, D31 | 0 Participants |
| Part B: mRNA CR-04 3 µg | Number of Participants With Vaccine Response Rate (VRR) Based on Neutralizing Titers Against Vaccine Encoded SARS-CoV-2 and WT Strains | D614G, D31 | 0 Participants |